DelveInsight’s ‘Food Allergy Pipeline Insight 2023‘ report provides comprehensive global coverage of available, marketed, and pipeline Food Allergy therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Food Allergy pipeline domain.
Key Takeaways from the Food Allergy Pipeline Report
Food Allergy Overview
A food allergy occurs when the body’s immune system sees a certain food as harmful and reacts by causing symptoms. This is an allergic reaction. Foods that cause allergic reactions are allergens. The results of skin prick tests (SPT), IgE total and specific antibodies, and patient histories are not predictive of true food allergy, as they are not able to establish the causal and temporal relationship between the intake of the suspect food and the hypersensitivity reaction.
The negative predictive accuracy of a skin prick test weal of < 3mm greater than the negative control is high, usually > 95%, and is strong evidence that the food may be consumed without severe, immediate food-allergic reactions. A positive SPT, even a weal of 3 mm or more, may be clinically irrelevant, as the patient may tolerate the ingested food. SPTs may also remain positive after the development of tolerance to the specific food. The foods to which an individual is allergic should be avoided, as therapeutic intervention (tertiary prevention) in patients with food allergy.
It must strike a precautionary equilibrium between the demands of prohibitive measures against allergy care and quality of life. Hypersensitivity reactions are often treated with medications. . Epinephrine is the only medication that is effective for the treatment of anaphylaxis. Additional medicatioons include H1 and H2 antihistamines, corticosteroids, and prostaglandin synthetase inhibitors.
Request for a sample report to know more about food allergy treatment algorithm and diagnosis.
Food Allergy Pipeline Analysis: Drug Profile
Viaskin Peanut: DBV technologies
Investigational Viaskin® Peanut therapeutic treatment is based on epicutaneous immunotherapy, or EPIT™. This potential new class of immunotherapey is designed to work by delivering allergens to the immune system through intact skin using our proprietary Viaskin® technology. For those patients facing potentially life-threatening food allergies, this potential immunotherapy treatment aims to desensitize them to allergens by delivering compounds in small quantities into the outer layers of the skin. The investigational EPIT aims to target specific epidermal dendritic cells, called Langerhans cells. Pre-clinical research has shown that these cells capture antigens and migrate to the lymph node in order to activate the immune system.
Discover more about the emerging Food Allergy drugs @ Food Allergy Treatment Drugs
Food Allergy Key Companies
Food Allergy Pipeline Therapies
Food Allergy Pipeline Therapeutics Assessment
Scope of the Food Allergy Pipeline Report
Find out more about the Food Allergy treatment options in development @ Food Allergy Clinical Trials
Table of Contents
1. Introduction
2. Executive Summary
3. Overview
4. Pipeline Therapeutics
5. Late-Stage Products (Phase III)
6. Mid-Stage Products (Phase II)
7. Early Stage Products (Phase I/II)
8. Preclinical Stage Products
9. Discovery Stage Products
10. Therapeutic Assessment
11. Inactive Products
12. Collaborations Assessment- Licensing / Partnering / Funding
13. Unmet Needs
14. Market Drivers and Barriers
15. Appendix
16. About DelveInsight
Other Trending Reports:
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences.
Contact Us
Kritika Rehani
[email protected]
+1(919)321-6187
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Kritika RehaniEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432 City: Las VegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/
